An elderly patient with painful Paget disease was treated for a period of one year with intramuscular injections of 100 Medical Research Council units of synthetic salmon calcitonin. During this period, she experienced marked improvement in her bone pain. The serum alkaline phosphatase level dropped from a pretreatment level of 7.8 to 1.4 Sigma units and the urinary hydroxyproline level fell from a pretreatment level of 69.3 to 21.3 mg/day. The lack of significant adverse reactions and the suppressive effects of calcitonin on the subjective and objective manifestations of Paget disease make this agent an important therapeutic advance.
Schuhmacher CA, Scurry MT, Deiss WP. Paget Disease of BoneLong-Term Treatment With Salmon Calcitonin. Arch Intern Med. 1973;131(5):722–724. doi:10.1001/archinte.1973.00320110106016